Zhao S, Kusminski CM, Scherer PE
100% authentic Thai premium product sourced directly from brand-authorized suppliers in Bangkok
should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus Discontinue treatment in women at least 2 months before a planned pregnancy, owing to the long washout period for semaglutide Clinical Considerations Poorly controlled diabetes during pregnancy increases maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, stillbirth, and delivery complications Poorly controlled diabetes increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity Lactation There are no data on the presence of semaglutide in human milk, the effects on the breastfed infant, or the effects on milk production In lactating rats, semaglutide was detected in milk at levels 3- to 12-fold lower than in maternal plasma Interactions Coadministration with insulin secretagogues (eg, sulfonylureas) or insulin may increase the risk of hypoglycemia
Future multicenter studies with longer follow-up periods are needed to validate these findings and better evaluate the long-term benefits and limitations of this treatment approach
CJC-1295 (No DAC) combined with Ipamorelin is a dual-peptide formulation currently under investigation for its interaction with growth hormonerelated signaling pathways
